Atypical antipsychotics and dopamine D1 receptor agonism: An in vivo experimental study using core temperature measurements in the rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 731-736

  Oerther, Sandra ^a   Ahlenius, Sven ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; QUINPIROLE; RISPERIDONE;

ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; CORE TEMPERATURE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; HYPOTHERMIA; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RAT; SCHIZOPHRENIA;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEVER; HYPOTHERMIA; MALE; PIRENZEPINE; QUINPIROLE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; RISPERIDONE; TIME FACTORS;

EID: 0033956650     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. 1A receptor agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 64:3-5.
2. 1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs. Pharmacol Toxicol 84:193-196.
3. Andén N-E (1980) Regulation of monoamine synthesis and utilization by receptors. Hand Exp Pharmacol 54:429-462.
4. 1 receptor. J Neurochem 47:1822-1831.
5. Auzou P, Ozsancak C, Hannequin D, Moore N and Augustin P (1996) Clozapine for the treatment of psychosis in Parkinson's disease: A review. Acta Neurol Scand 94:329-336.
6. Barnes TR and McPhillips MA (1998) Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 13:S49-S57.
7. 1-like receptors and reward-related incentive learning. Neurosci Biobehav Rev 22:335-345.
8. 1 receptor agonist dihydrexidine in Parkinson's disease. Clin Neuropharmacol 21:339-343.
9. 4 receptor antagonist. Trends Pharmacol Sci 18:186-188.
10. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT and Moore NA (1997) In vitro and in vivo biochemistry of olanzapine: A novel atypical antipsychotic drug. J Clin Psychiatry 58:28-36.
11. 2-dopamine receptor occupancy during treatment with conventional and atypical antipsychotics. Psychopharmacology 99:S28-S31.
12. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544.
13. Farde L and Sedvall G (1995) Chemical brain anatomy of schizophrenia. Lancet 346:743-749.
14. 1 receptor antagonist SCH23390. Life Sci 56:365-368.
15. 1-dopamine receptors. J Nucl Med 39:2061-2068.
16. Hamner MB and Arana GW (1998) Hyperprolactinaemia in antipsychotic-treated patients: Guidelines for avoidance and management. CNS Drugs 10:209-222.
17. Heh CW, Herrera J, DeMet E, Potkin S, Costa J, Sramek J, Hazlett E and Buchsbaum MS (1988) Neuroleptic-induced hypothermia associated with amelioration of psychosis in schizophrenia. Neuropsychopharmacology 1:149-156.
18. 2 adrenoceptor blockade. Science (Wash DC) 286:105-107.
19. Hertel P, Nomikos GG, Iurlo M and Svensson TH (1996) Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 124:74-86.
20. Hillegaart V and Ahlenius S (1994) Time course for synchronization of spontaneous locomotor activity in the rat following reversal of the daylight (12:12 h) cycle. Physiol Behav 55:73-75.
21. Ingvar D (1987) Evidence for frontal/prefrontal cortical dysfunction in chronic schizophrenia: The phenomenon of "hypofrontality" reconsidered, in Biological Perspectives of Schizophrenia (Helmchen H and Henn FA eds) pp 201-211, Wiley, Chichester.
22. 2 receptors? Psychopharmacology 138:213-214.
23. 2A antagonist with favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981.
24. Keppel G (1982) Design and Analysis, Prentice-Hall, Englewood Cliffs, NJ.
25. Kuroki T, Meltzer HY and Ischikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781.
26. Lewander T, Westerbergh SE and Morrison D (1990) Clinical profile of remoxipride: A combined analysis of a comparative double-blind multicenter trial program. Acta Psychiatr Scand 82:92-98.
27. Li CC (1964) Introduction to Experimental Statistics, pp 207-226, McGraw-Hill, New York.
28. Li XM, Perry KW, Wong DT and Bymaster FP (1998) Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 136:153-161.
29. Lidow MS, Williams GV and Goldman-Rakic PS (1998) The cerebral cortex: A case for a common site of action of antipsychotics. Trends Pharmacol Sci 19:136-140.
30. 1-like receptors. Schizophren Res 36:116.
31. Mansour A and Watson SJ (1995) Dopamine receptor expression in the central nervous system, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 207-219, Raven Press, New York.
32. 1A receptors in human brain tissue. Eur J Pharmacol 221:397-398.
33. Meltzer HY (1995) Multiple outcome criteria in schizophrenia: An overview of outcome with clozapine. Eur Psychiatr 19 (Suppl 10):9S-25S.
34. 2 pKi values. J Pharmacol Exp Ther 251:238-246.
35. Meltzer HY and McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophren Bull 25:233-255.
36. 2 receptors in dopamine depleted animals. Psychopharmacology 142:175-181.
37. 2 receptors in dopamine depleted animals. Psychopharmacology 135:311-317.
38. 1 receptors in schizophrenia revealed by PET. Nature (Lond) 385:634-636.
39. Owens MJ and Risch SC (1998) Atypical antipsychotics, in Textbook of Psychopharmacology (Schatzberg AF and Nemeroff CB eds) pp 323-348, The American Psychiatric Press, Washington, DC.
40. Parfitt K (ed) (1999) Martindale: The Complete Drug Reference, 32nd ed., pp 635-700, Pharmaceutical Press, London.
41. 1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated l-dopa-primed common marmosets. Psychopharmacology 142:51-60.
42. Pehek EA (1996) Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. Synapse 24:12-18.
43. Petty RG (1999) Prolactin and antipsychotic medications: Mechanism of action. Schizophren Res 35:S67-S73.
44. 1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol 45:736-741.
45. 1A receptor activation. Eur J Pharmacol 338:R3-R5.
46. 2/3 receptors in rat thermoregulation. Brain Res 781:188-193.
47. 1 receptor agonist. Eur J Pharmacol 307:27-31.
48. 2 receptors in the regulation of body temperature in the rat. Eur J Pharmacol 236:395-400.
49. Salmi P, Karlsson T and Ahlenius S (1994) Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat. Eur J Pharmacol 253:67-73.
50. Salmi P, Malmgren K, Svensson TH and Ahlenius S (1998) Stimulation of forward locomotion by SCH-23390 and raclopride in d-amphetamine-treated rats. Naunyn-Schmiedeberg's Arch Pharmacol 357:593-599.
51. 2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 273:273-279.
52. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K and Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
53. Seeman P (1980) Dopamine receptors. Pharmacol Rev 32:229-313.
54. Tamminga C and Gerlach J (1987) New neuroleptics and experimental antipsychotics in schizophrenia, in Psychopharmacology: The Third Generation of Progress (Meltzer HY ed) pp 1129-1140, Raven Press, New York.
55. Waddington JL (1989) Functional interactions between D-1 and D-2 dopamine receptor systems: Their role in the regulation of psychomotor behaviour, putative mechanisms and clinical relevance. J Psychopharmacol 3:54-63.
56. 2 receptor blocking agent ritanserin, in the rat. Eur Neuropsychopharmacol 6:305-310.
57. Winer BJ (1971) Statistical Principles in Experimental Design, McGraw-Hill, New York.
58. Yehuda S (1977) Hypothermic effects of antipsychotic phenothiazines, in The Impact of Biology on Modern Psychiatry (Gershon ES ed) pp 137-148, Plenum, New York.
59. Youngren KD, Inglis FM, Pivirotto PJ, Jedema HP, Bradberry CW, Goldman-Rakic PS, Roth RH and Moghaddam B (1999) Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20:402-412.
60. Zelman S and Guillman R (1970) Heat stroke in phenothiazine treated patients: A report of three fatalities. Am J Psychiatry 126:129-132.
61. 2A and muscarinic receptors. Psychopharmacology 141:267-278.